Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Amgen will release its first quarter financial results on April 27, 2023, post market closure. The announcement will be followed by a conference call at 1:30 p.m. PT, featuring CEO Robert A. Bradway and senior management. Participants can access a live audio broadcast of the call, which will be available for replay for at least 90 days. Amgen, a leading biotechnology firm with a rich pipeline of medicines, was recognized in 2022 by Forbes as one of the "World's Best Employers" and by Barron's as one of "America's 100 Most Sustainable Companies." The company is part of both the Dow Jones Industrial Average and the Nasdaq-100 index.
Amgen announced that the U.S. Court of Appeals for the Federal Circuit upheld the validity of its patent for Otezla (apremilast), which is set to expire in February 2028. This ruling affirms a previous injunction preventing Sandoz and Zydus Pharmaceuticals from producing generic versions of Otezla during this period. The court validated U.S. Patent No. 7,427,638 and U.S. Patent No. 7,893,101 related to Otezla, while ruling against Amgen on U.S. Patent No. 10,092,541. Otezla is approved for treating plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's Disease.
Foresee Pharmaceuticals announced the appointment of Dr. Bassem Elmankabadi as Senior Vice President of Clinical Development on April 17, 2023. Dr. Elmankabadi brings over 17 years of clinical experience, previously holding leadership roles at Amgen (NASDAQ: AMGN) and FibroGen (NASDAQ: FGEN). His experience includes negotiating four Clinical Development Plans for Phase 2 and 3 studies for the company's drugs, Cudetaxestat and Pamrevlumab. Dr. Elmankabadi's background includes surgical leadership and clinical instruction at UCLA. Foresee Pharmaceuticals focuses on innovative therapies, with key products including CAMCEVI for advanced prostate cancer, approved in the U.S., Canada, and EU, as well as other promising candidates in clinical development.